<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>DRREDDY</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">DRREDDY</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="dr.-reddys-laboratories-limited" class="section level1">
<h1>Dr. Reddy’s Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.DRREDDY.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p><strong>Dr. Reddy’s Laboratories Ltd. (DRREDDY / 500124 / RDY) – Analysis of Headwinds, Tailwinds, Growth Prospects &amp; Key Risks</strong><br />
<em>As of December 2025 – Based on Q2 FY26 Results &amp; Subsequent Disclosures</em></p>
<hr />
<div id="executive-summary" class="section level9">
<p class="heading"><strong>Executive Summary</strong></p>
<p>Dr. Reddy’s Laboratories delivered <strong>resilient performance in Q2 FY26 (Sep 2025)</strong> with <strong>near double-digit revenue growth (9.8% YoY)</strong>, sustained EBITDA margins at <strong>26.7%</strong>, and <strong>14% YoY PAT growth to ₹1,437 Cr</strong>. Despite headwinds in North America due to price erosion and decline in Lenalidomide sales, the company reported broad-based growth across geographies including <strong>strong momentum in India, Europe (boosted by NRT acquisition), and Emerging Markets (EM) driven by new launches and favorable forex</strong>.</p>
<p>Strategic progress in <strong>biosimilars (denosumab approval in EU)</strong>, innovation in specialty (PCAB®, Colozo®), in-licensing, M&amp;A (Stugeron®), and ESG advancements highlights its long-term growth trajectory. However, <strong>regulatory scrutiny has increased</strong>, and <strong>short-term margin pressure persists due to mix and integration costs</strong>.</p>
<p>The company remains in a <strong>net cash surplus position (~₹2,751 Cr)</strong>, offering strategic flexibility for capital allocation and growth initiatives.</p>
<hr />
</div>
<div id="i.-key-financials-q2-fy26-sep-2025" class="section level6">
<h6><strong>I. Key Financials (Q2 FY26 – Sep 2025)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26 (Sept 2025)</th>
<th>YoY Growth</th>
<th>QoQ Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenues</strong></td>
<td>₹8,805 Cr</td>
<td><strong>+9.8%</strong></td>
<td>+3%</td>
</tr>
<tr class="even">
<td><strong>EBITDA</strong></td>
<td>₹2,351 Cr</td>
<td>+3%</td>
<td>+3%</td>
</tr>
<tr class="odd">
<td><strong>EBITDA Margin</strong></td>
<td><strong>26.7%</strong></td>
<td>-1.7 ppt</td>
<td>Stable</td>
</tr>
<tr class="even">
<td><strong>PBT</strong></td>
<td>₹1,835 Cr</td>
<td>+4%</td>
<td>+4%</td>
</tr>
<tr class="odd">
<td><strong>PAT (Attributable)</strong></td>
<td>₹1,437 Cr</td>
<td><strong>+14%</strong></td>
<td>+1%</td>
</tr>
<tr class="even">
<td><strong>EPS (Diluted)</strong></td>
<td>₹17.25</td>
<td>+15%</td>
<td>+1%</td>
</tr>
<tr class="odd">
<td><strong>RoCE (Annualised)</strong></td>
<td>~<strong>22%</strong></td>
<td>Slight dip</td>
<td>-</td>
</tr>
<tr class="even">
<td><strong>Capex</strong></td>
<td>₹511 Cr (QoQ increase)</td>
<td></td>
<td>+74%</td>
</tr>
</tbody>
</table>
<blockquote>
<p><em>Note: Underlying growth ex-NRT at <strong>+17% YoY in Europe</strong>, highlighting organic momentum.</em></p>
</blockquote>
<hr />
</div>
<div id="ii.-business-highlights-tailwinds-growth-drivers" class="section level6">
<h6><strong>II. Business Highlights – Tailwinds (Growth Drivers)</strong></h6>
<div id="diversified-global-generics-momentum" class="section level9">
<p class="heading"><strong>1. Diversified Global Generics Momentum</strong></p>
<ul>
<li><strong>Global Generics Revenues</strong>: ₹7,850 Cr (+10% YoY)
<ul>
<li><strong>India (₹1,578 Cr, +13% YoY)</strong> – Led by new brand launches (PCAB®, Colozo®), volume growth, and improved pricing.
<ul>
<li>Ranked <strong>#9 in IPM</strong> (Sep 2025) with <strong>23 brands &gt; ₹100 Cr</strong>.</li>
<li>Therapy leadership: <strong>#1 in Stomatologicals</strong>, #2 in Vaccines.</li>
</ul></li>
<li><strong>Emerging Markets (₹1,655 Cr, +14% YoY)</strong> – Fueled by new product launches (24 in Q2) and favorable forex (e.g., Russia +28% YoY).
<ul>
<li>Russia: ₹875 Cr (~7% of total revenue); market outperformed peers.</li>
</ul></li>
<li><strong>Europe (₹1,376 Cr, +138% YoY)</strong> – Driven by <strong>NRT acquisition (₹700 Cr revenue)</strong> and integration (2/3 value integrated).</li>
<li><strong>North America (₹3,241 Cr, +13% YoY)</strong> – Resilient despite erosion, with new launches (Sacubitril/Valsartan, Fluorouracil cream) and ANDA pipeline.</li>
</ul></li>
</ul>
</div>
<div id="innovation-pipeline-advancements" class="section level9">
<p class="heading"><strong>2. Innovation &amp; Pipeline Advancements</strong></p>
<ul>
<li><strong>India launches</strong>:
<ul>
<li><strong>Tegoprazan (PCAB®)</strong> – Novel drug in acid-related GI diseases.</li>
<li><strong>Linaclotide (Colozo®)</strong> – For chronic constipation.</li>
</ul></li>
<li><strong>EMA’s CHMP positive opinion → EU biosimilar approval</strong>:
<ul>
<li><strong>AVT03 (denosumab biosimilar)</strong> for Prolia® &amp; Xgeva® — approved by <strong>European Commission (Nov 2025)</strong>.
<ul>
<li>To be marketed as <strong>Acvybra®</strong> (syringe) and <strong>Xbonzy®</strong> (vial).</li>
<li>Partnership with <strong>Alvotech</strong> supports global rollout (EU + UK semi-exclusive, US exclusive).</li>
</ul></li>
</ul></li>
<li><strong>COYA 302 IND accepted by USFDA</strong> – A novel oncology candidate.</li>
</ul>
</div>
<div id="strategic-ma-in-licensing" class="section level9">
<p class="heading"><strong>3. Strategic M&amp;A &amp; In-Licensing</strong></p>
<ul>
<li><strong>Acquisition of Stugeron® &amp; related Janssen brands</strong> across <strong>18 APAC &amp; EMEA markets</strong> for <strong>$50 million</strong>.
<ul>
<li>Reinforces India portfolio and access to key emerging markets.</li>
<li>Gradual transition ongoing.</li>
</ul></li>
<li><strong>Strengthening emerging markets presence:</strong> Now in <strong>48 countries</strong> (EM).</li>
</ul>
</div>
<div id="esg-strengths-operational-excellence" class="section level9">
<p class="heading"><strong>4. ESG Strengths &amp; Operational Excellence</strong></p>
<ul>
<li><strong>MSCI ESG Rating: ‘A’</strong> (2nd consecutive year).</li>
<li><strong>Sustainalytics ESG Risk Rating: 18.4</strong> (low risk).</li>
<li><strong>Waste diversion: 99.9% landfill-free</strong> (‘Diamond Standard’ by TÜV SÜD).</li>
<li><strong>LEED Platinum certification</strong> for FTO-11, Srikakulam – <strong>first Indian pharma plant to achieve this</strong>.</li>
<li><strong>Net cash surplus: ₹2,751 Cr</strong> – Strong balance sheet flexibility.</li>
</ul>
<hr />
</div>
</div>
<div id="iii.-headwinds-challenges" class="section level6">
<h6><strong>III. Headwinds &amp; Challenges</strong></h6>
<div id="price-erosion-mix-issues-in-north-america" class="section level9">
<p class="heading"><strong>1. Price Erosion &amp; Mix Issues in North America</strong></p>
<ul>
<li><strong>North America under pressure</strong> due to:
<ul>
<li><strong>Generalized price erosion</strong> in generics market.</li>
<li><strong>Decline in Lenalidomide sales</strong> (high-margin product).</li>
</ul></li>
<li>Despite 13% YoY growth, Q2 growth <strong>lagged behind market (+0.1% vs -2.1% IQVIA MAT)</strong> – shows some recovery but still challenging.</li>
<li><strong>Pending approvals</strong>: 73 ANDAs (incl. 46 Para-IV, 20 FTF), indicating potential future upside.</li>
</ul>
</div>
<div id="margin-pressure-in-psai-gm" class="section level9">
<p class="heading"><strong>2. Margin Pressure in PSAI &amp; GM</strong></p>
<ul>
<li><strong>PSAI Segment</strong>: ₹945 Cr (+12% YoY) but <strong>gross margin declined from 30% to 10% YoY</strong>.
<ul>
<li>Due to <strong>product mix shifts and lower operating leverage</strong>.</li>
</ul></li>
<li><strong>Gross Margin down to 54.7% (from 59.6% YoY)</strong> – impacted by:
<ul>
<li>Mix (lower-margin biosimilars/NRT).</li>
<li>NRT integration costs.</li>
<li>VAT provision (one-off in Q1).</li>
</ul></li>
<li><strong>RoCE softened to ~22%</strong> (from 27.5% in Q2 FY25).</li>
</ul>
</div>
<div id="regulatory-scrutiny" class="section level9">
<p class="heading"><strong>3. Regulatory Scrutiny</strong></p>
<ul>
<li><strong>USFDA issued Form 483s</strong>:
<ul>
<li><strong>Bachupally (biologics facility)</strong> – 5 observations.</li>
<li><strong>Mirfield, UK (API facility)</strong> – 7 observations.</li>
</ul></li>
<li><strong>Voskresensk (Middleburg)</strong> plant classified <strong>‘VAI’</strong> post-Russia GMP inspection.</li>
<li><strong>No red flags</strong>, but delays in approvals or compliance upgrades could impact supply and growth.</li>
</ul>
</div>
<div id="integration-risks-nrt-acquisition" class="section level9">
<p class="heading"><strong>4. Integration Risks – NRT Acquisition</strong></p>
<ul>
<li>High growth in Europe is <strong>influenced by NRT acquisition</strong>.</li>
<li>While <strong>2/3rd business value integrated</strong>, full integration success will determine synergy realization and margin improvement.</li>
</ul>
<hr />
</div>
</div>
<div id="iv.-growth-prospects-strategic-focus-20252027" class="section level6">
<h6><strong>IV. Growth Prospects &amp; Strategic Focus (2025–2027)</strong></h6>
<table>
<colgroup>
<col width="68%" />
<col width="32%" />
</colgroup>
<thead>
<tr class="header">
<th>Area</th>
<th>Growth Drivers</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Core Generics</strong></td>
<td>India double-digit growth, EM expansion, new launches (US/Europe), ANDA pipeline (73 pending).</td>
</tr>
<tr class="even">
<td><strong>Innovative Brands (India)</strong></td>
<td>PCAB®, Colozo® – novel GI launches offer premium margins and leadership.</td>
</tr>
<tr class="odd">
<td><strong>Biosimilars</strong></td>
<td><strong>EU approval of AVT03</strong> – major in Europe. <strong>Versavo® (bevacizumab)</strong> already launched in UK. US biosimilar launches via partners. Expansion of biologics capacity.</td>
</tr>
<tr class="even">
<td><strong>Specialty &amp; Pipeline</strong></td>
<td><strong>COYA 302 (oncology) IND accepted</strong> – early-stage but promising. Partnerships (e.g. Alvotech) derisk development.</td>
</tr>
<tr class="odd">
<td><strong>Emerging Markets</strong></td>
<td>Broad footprint in Russia, CIS, and ROW. Local manufacturing &amp; localization strategies.</td>
</tr>
<tr class="even">
<td><strong>M&amp;A / In-Licensing</strong></td>
<td>Acquisitions like <strong>Stugeron®</strong> show focus on value-add brands. Further bolt-ons likely in APAC/EM.</td>
</tr>
<tr class="odd">
<td><strong>Ecosystem Investments</strong></td>
<td>Digital, quality compliance, ESG leadership – long-term cost discipline and access.</td>
</tr>
</tbody>
</table>
<blockquote>
<p><em>FY26 revenue guidance implied at ~10% YoY growth, with EBITDA margin above 25%.</em></p>
</blockquote>
<hr />
</div>
<div id="v.-key-risks" class="section level6">
<h6><strong>V. Key Risks</strong></h6>
<table>
<colgroup>
<col width="69%" />
<col width="30%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Specific Risks</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Commercial Risks</strong></td>
<td>- Sustained <strong>price erosion in US generics market</strong>. <br> - Dependence on <strong>few key products (e.g. Lenalidomide)</strong>. <br> - Competition from complex generics space.</td>
</tr>
<tr class="even">
<td><strong>Regulatory Risks</strong></td>
<td>- <strong>Ongoing USFDA inspections (Form 483)</strong> and remediation timeline. <br> - Potential for import alerts or delays in ANDA approvals. <br> - <strong>CDSCO / EMA / FDA scrutiny in biosimilars space</strong>.</td>
</tr>
<tr class="odd">
<td><strong>Geopolitical Risks</strong></td>
<td>- <strong>Russia market volatility</strong> (sanctions, forex, logistics). <br> - Dependency on CIS market (14% of EM).</td>
</tr>
<tr class="even">
<td><strong>Financial &amp; Currency Risks</strong></td>
<td>- <strong>Rupee appreciation</strong> could hurt export margins. <br> - Rising <strong>interest rates</strong> impacting capex/cost of capital.</td>
</tr>
<tr class="odd">
<td><strong>Integration &amp; Execution Risk</strong></td>
<td>- Successful integration of <strong>NRT and Stugeron</strong> is key. <br> - M&amp;A multiples and synergy delivery.</td>
</tr>
<tr class="even">
<td><strong>Tax &amp; Legal Risks</strong></td>
<td>- <strong>GST Appellate Order (Nov 2025)</strong>: penalty ₹3.47 Lakh (not material, but highlights tax audit exposure). <br> - Potential for future disputes.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="vi.-conclusion-investment-thesis-neutral-to-positive-bias" class="section level6">
<h6><strong>VI. Conclusion: Investment Thesis – Neutral to Positive Bias</strong></h6>
<div id="strengths" class="section level9">
<p class="heading"><strong>Strengths</strong>:</p>
<p>✅ <strong>Diversified global footprint</strong> across 83 markets.<br />
✅ <strong>Robust new product pipeline</strong> in generics, biosimilars, and branded generics.<br />
✅ <strong>Strategic M&amp;A and acquisitions</strong> enhancing brand footprint.<br />
✅ <strong>Strong ESG profile</strong> enhances valuation and sustainability of operations.<br />
✅ <strong>Healthy cash flow &amp; net cash surplus</strong> – financial resilience.</p>
</div>
<div id="challenges" class="section level9">
<p class="heading"><strong>Challenges</strong>:</p>
<p>⚠️ <strong>Margin pressures</strong> in PSAI and overall GM.<br />
⚠️ <strong>Regulatory cloud over US facilities</strong> requires active monitoring.<br />
⚠️ <strong>North America dynamics</strong> remain tough despite new launches.</p>
</div>
<div id="outlook" class="section level9">
<p class="heading"><strong>Outlook</strong>:</p>
<ul>
<li><strong>Near-term growth (~10% CAGR)</strong> supported by <strong>India, EM, acquired assets, and biosimilars</strong>.</li>
<li><strong>Long-term growth accelerator</strong>: Biosimilars pipeline (AVT03, upcoming assets) and specialty (COYA 302).</li>
<li><strong>Valuation</strong>: Trading at moderate P/E (~30–32x FY26 EPS), justified by global scale and innovation transition.</li>
</ul>
<blockquote>
<p><strong>Rating</strong>: <strong>Accumulate</strong> (for long-term investors), <strong>Hold</strong> (trading at fair value).<br />
<strong>Watch triggers</strong>:<br />
- Biosimilar launches in US/EU.<br />
- Resolution of USFDA Form 483s.<br />
- Margin recovery in H2 FY26.<br />
- Further strategic in-licensing/M&amp;A.</p>
</blockquote>
<hr />
<p><strong>Prepared as of: December 2025</strong><br />
<em>Sources: Q2 FY26 Investor Presentation, Press Releases, GST Notice, Regulatory Filings</em></p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
